Biogen Q4 revenue up 3% to $2.5B, non-GAAP EPS $3.44; FY2025 guidance calls for revenue decline

BIOGEN INC.

2024-FY EPS reported $11.18 revenue$9,675,900,000

Q4 total revenue $2.5B (+3% YoY); GAAP EPS $1.83, non-GAAP EPS $3.44 (+17% YoY).
Full year 2024 revenue $9.7B (-2% YoY); non-GAAP EPS $16.47 (+12% YoY).
LEQEMBI global in-market sales ~$87M; SKYCLARYS revenue ~$102M, patient count nearly doubled vs end 2023.
Regulatory milestones: LEQEMBI subcutaneous BLA accepted (PDUFA Aug 31, 2025); nusinersen higher dose filings accepted (PDUFA Sep 22, 2025).
FY2025 guidance: non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit % at constant currency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.